Objective: To assess the cost-effectiveness of clopidogrel versus aspirin for high risk patients
(pre-existing symptomatic atherosclerosis or multi-vascular territory involvement) with …

Clopidogrel has been shown to reduce the secondary risk of ischaemic events in vascular
disease compared to aspirin. This article compares the economics of the two drugs for this …

Background: Atherothrombosis represents a leading cause of morbidity and mortality
worldwide. Given the prominent role of platelet aggregation in atherothrombosis, antiplatelet …

Objectives To evaluate in peripheral arterial disease two strategies of antiplatelet therapy
(clopidogrel and aspirin) in terms of number of ischemic stroke and hemorrhagic events, to …

Atherothrombosis is the leading cause of death worldwide, responsible for 22% of all deaths
annually.[1] Ischaemic vascular events such as myocardial infarction (MI) and ischaemic …

Objectives: To model the 2-year cost-effectiveness of secondary prevention with clopidogrel
versus aspirin (acetylsalicylic acid)(ASS) in German patients with myocardial infarction (MI) …

Abstract Background and Objectives Clopidogrel or aspirin are indicated for patients with
recent ischemic stroke (IS) or established peripheral artery disease (PAD). We compared the …

Atherothrombotic disease is a growing health problem, and is increasingly more costly to
manage. Clopidogrel is an advanced, specific adenosine diphosphate receptor antagonist …

The recent multinational, randomised, prospective studies Clopidogrel in Unstable Angina to
Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention substudy of CURE …

Background Antiplatelet therapy plays a central role in the prevention of atherothrombotic
events. Both acetylsalicylic acid (aspirin) and Clopidogrel have been shown to reduce the …